This data-driven approach indicates that the mCHR-GFP-LC3 sensor reports the modes of action of chemotherapeutic perturbations on the autophagic flux and suggests specific modes of action for epirubicin, cisplatin and paclitaxel across three different breast cancer cell lines. Here, MAP1LC3A is linked to breast carcinoma.